California medical device maker TriVascular Technologies is looking to raise as much as $100 million through its initial public offering, the details of which have yet to be finalized.
Endoscopic
Covidien closes $860M Given Imaging buy
Covidien (NYSE:COV) said it closed the buyout of Given Imaging and its PillCam imaging device for about $860 million, net of cash and investments.
Gore’s Viabahn stent graft bests angioplasty, study finds
Arizona medical device maker W.L. Gore & Assoc. teased positive results from its REVISE clinical trial, promising to release additional findings during the American Society of Diagnostic & Interventional Nephrology meeting in Phoenix this week.
Cordis releases 2-year data from Incraft stent trial
Cordis Corp, a Johnson & Johnson (NYSE:JNJ) subsidiary, released 2-year data from its INNOVATION trial testing the safety and performance of the Incraft abdominal aortic aneurysm stent graft system.
Medtronic lands expanded FDA approval for Valiant Captivia
EndoChoice lands Canadian nod for colonoscope
EndoChoice said it won a marketing license in Canada for its Fuse endoscopy system.
The Fuse endoscope features 3 small cameras that provide a 330-degree view, nearly double the range of typical colonoscopy devices.
The Fuse device won FDA 510(k) clearance in the U.S. in June 2013.
Avantis raises $5M in debt round for Third Eye endoscope
Avantis Medical Systems said it brought in $4.8 million of a hoped-for $10.6 million debt round.
Sunnyvale, Calif.-based Avantis makes catheter-based endoscopic devices designed to detect and treat and gastrointestinal cancers, according to its website. It’s flagship product is the Third Eye "retrospect" for colonoscopies.
London’s Lombard Medical seeks U.S. IPO
TriVascular adds $2M in options round
TriVascular Inc. sold $1.9 million in an options offering, adding to a $40 million Series E funding round it logged last month.
Santa Rosa, Calif.-based TriVascular makes the Ovation line of stent grafts for treating abdominal aortic aneurysms.
The company sold options and convertible notes to 2 unnamed investors, according to a regulatory filing.
Gore appeals $860M loss to Bard
C.R. Bard (NYSE:BCR) had no standing to bring the patent infringement lawsuit that won it a nearly $860 million verdict against W.L. Gore & Assoc., Gore argued in its appeal yesterday.
Bolton begins U.S. clinical trial for Treovance abdominal stent graft
Bolton Medical launched phase II of its U.S. clinical trial for its Treovance abdominal stent graft system and corresponding Navitel delivery system.
The Treovance stent graft is designed to be adaptable and flexible in order to accommodate a wide range of anatomies. The Navitel delivery system includes a proximal clasping system for precise delivery.
The phase II study will treat 150 patients with infrarenal aortic aneurysms, enrolled at 30 institutions located throughout the U.S., according to the press release.